PedAM
Pediatric Disease Annotations & Medicines
| Disease | schizophrenia |
| Symptom | C0948265|metabolic syndrome |
| Sentences | 47 |
| PubMedID- 24955550 | Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study. |
| PubMedID- 26093599 | The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial. |
| PubMedID- 25126357 | Objectives: to summarize the current literature on atypical antipsychotic-induced metabolic syndrome in patients with schizophrenia, outline some of the molecular mechanisms behind this syndrome, identify demographic and disease-related risk factors, and describe cost-effective methods for surveillance. |
| PubMedID- 23960421 | Despite expected controversies, some patient-related risk factors for the development of metabolic syndrome in patients with schizophrenia receiving atypical antipsychotic drugs are found in the literature. |
| PubMedID- 21772644 | Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. |
| PubMedID- 21994515 | Genetic polymorphisms in the htr2c and peroxisome proliferator-activated receptors are not associated with metabolic syndrome in patients with schizophrenia taking clozapine. |
| PubMedID- 23882141 | This study showed that the prevalence of metabolic syndrome in patients with schizophrenia was higher than the overall rate but was slightly lower than in the general population in the usa. |
| PubMedID- 22796278 | Moreover, strategies to reduce inflammation and obesity may prevent metabolic syndrome in patients with schizophrenia who take atypical antipsychotic medication. |
| PubMedID- 22044502 | Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a german observational study. |
| PubMedID- 23337566 | Conclusion: the prevalence of metabolic syndrome in schizophrenia patients receiving antipsychotic monotherapy in malaysia was very high. |
| PubMedID- 22754543 | Finally, preliminary evidence suggests that folate supplementation, which may restore balance of the aldo met cycle, improves endothelial function in schizophrenia patients with metabolic syndrome (ellingrod et al., 2012). |
| PubMedID- 24837425 | metabolic syndrome is associated with both schizophrenia and antipsychotic medication, especially clozapine, with alterations in inflammatory cytokines and adipokines. |
| PubMedID- 23153955 | The aetiology of the metabolic syndrome in schizophrenia is multi-factorial and may involve antipsychotic treatment, high levels of stress and unhealthy lifestyle, such as poor diet. |
| PubMedID- 22503355 | Prevalence of metabolic syndrome in patients with schizophrenia in india. |
| PubMedID- 24661388 | The cohorts varied in sample size (from hundreds to over half a million participants), in methodology and in the outcomes studied (height, overweight and obesity, glucose metabolism and diabetes, hypertension, metabolic syndrome, quality of life, schizophrenia, socioeconomic parameters etc.). |
| PubMedID- 23341251 | Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate. |
| PubMedID- 26041435 | Particularly, cognitive impairment, a core symptom of schizophrenia, is associated with metabolic syndrome5758 and chronic inflammation19. |
| PubMedID- 23286356 | schizophrenia patients with metabolic syndrome (mets) (35%) had a 23.9% lower (p<0.001) sbj-score and 22.4% (p<0.001) lower 6mwt-score than those without mets. |
| PubMedID- 25034455 | Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics. |
| PubMedID- 22154487 | metabolic syndrome in patients with schizophrenia independently from atypical antipsychotics intake. |
| PubMedID- 21398211 | In this article i review the theoretical and practical aspects of the comorbidity of schizophrenia with metabolic syndrome and diabetes mellitus. |
| PubMedID- 22869990 | Obesity and metabolic syndrome coexist with schizophrenia with or occasionally even without concurrent drug therapy. |
| PubMedID- 24204153 | Sod2 also plays crucial roles in antioxidant defense mechanisms.31 the val16ala polymorphism has been linked to cardiovascular disease and to type 2 diabetes and its complications in the general population, but studies so far have yielded conflicting results.28,29,33 in the present study, we did not find any significant associations between the sod2 genotype and the risks of being overweight and having metabolic syndrome in patients with schizophrenia or controls. |
| PubMedID- 22120854 | Prevalence of diabetes, obesity, and metabolic syndrome in subjects with and without schizophrenia (cures-104). |
| PubMedID- 22970386 | To improve quality of life and decrease metabolic syndrome in patients with schizophrenia, it is essential for caregivers to support patients' drug administration with a minimal effective dose, and aripiprazole is considered to be one of the most effective options available. |
| PubMedID- 26004686 | We aimed to determine the prevalence of metabolic syndrome among patients with schizophrenia who were antipsychotic drug-naive or drug-free and their siblings for comparison with healthy controls. |
| PubMedID- 21105277 | The prevalence of the metabolic syndrome is increased in patients with schizophrenia compared with the general population. |
| PubMedID- 20683849 | The objective of this multinational, cross-sectional, pharmacoepidemiological study was to determine the prevalence of diabetes, lipid disorders, obesity, hypertension and the metabolic syndrome in patients with schizophrenia treated with antipsychotic drugs. |
| PubMedID- 25568478 | Cardiac risk factors and metabolic syndrome in patients with schizophrenia admitted to a general hospital psychiatric unit. |
| PubMedID- 26469976 | Recent evidence has shown that schizophrenia is closely associated with hypertension , obesity , and dyslipidemia . |
| PubMedID- 22592510 | Conclusion: the metabolic syndrome development profile in patients with schizophrenia receiving atypical antipsychotic drugs in neas seems to be comparable to that in european and north american societies, especially when, among neas, high-risk societies are concerned. |
| PubMedID- 20425584 | metabolic syndrome associated with schizophrenia and atypical antipsychotics. |
| PubMedID- 22747854 | Predictive utility of blood pressure, waist circumference and body mass index for metabolic syndrome in patients with schizophrenia in singapore. |
| PubMedID- 21185157 | Association between htr2c polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. |
| PubMedID- 22986004 | schizophrenia is statistically associated with metabolic syndrome, hypertension, and migraine because they form a cluster of diseases with similar pathophysiology. |
| PubMedID- 21477998 | Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the clamors study. |
| PubMedID- 21791046 | This study aimed to investigate the degree that antipsychotic polypharmacy contributed to metabolic syndrome in outpatients with schizophrenia, after adjustment for the effects of lifestyle. |
| PubMedID- 22841467 | metabolic syndrome in patients with schizophrenia and antipsychotic treatment. |
| PubMedID- 24647221 | The aim of this study was to investigate the characteristics of cognitive function damage in chronic schizophrenia patients with metabolic syndrome (ms); 388 patients were divided into two groups: ms group (180 people with schizophrenia and ms) and non-ms group (208 people with schizophrenia but without ms). |
| PubMedID- 25917886 | The principal objective of this study was to investigate the relationship between sensory gating deficit and metabolic syndrome in patients with schizophrenia, after adjusting for key confounding factors. |
| PubMedID- 20850274 | Prevalence of metabolic syndrome among patients with schizophrenia in japan. |
| PubMedID- 22926590 | Higher prevalence rates of metabolic syndrome (mets) in patients with schizophrenia are getting more and more attention. |
| PubMedID- 23188979 | 2 found that the age-adjusted prevalence of metabolic syndrome in patients with schizophrenia was 40.9%, based on the criteria from the third report of the national cholesterol education program's expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) (ncep atp iii). |
| PubMedID- 23270504 | Prevalence of metabolic syndrome among patients with schizophrenia in palestine. |
| PubMedID- 23138143 | Prevalence of metabolic syndrome among patients with schizophrenia in singapore. |
| PubMedID- 22541717 | Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. |
| PubMedID- 26001844 | It has been estimated that the prevalence of metabolic syndrome in patients with schizophrenia may be as high as one in three 7. |
Page: 1